367 related articles for article (PubMed ID: 17676319)
1. Voriconazole and fluconazole increase the exposure to oral diazepam.
Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
[TBL] [Abstract][Full Text] [Related]
2. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyryläinen H; Laine K
Antimicrob Agents Chemother; 2006 Jun; 50(6):1967-72. PubMed ID: 16723553
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
4. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
[TBL] [Abstract][Full Text] [Related]
7. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.
Saari TI; Laine K; Neuvonen M; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2008 Jan; 64(1):25-30. PubMed ID: 17987285
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia.
Inomata S; Nagashima A; Itagaki F; Homma M; Nishimura M; Osaka Y; Okuyama K; Tanaka E; Nakamura T; Kohda Y; Naito S; Miyabe M; Toyooka H
Clin Pharmacol Ther; 2005 Dec; 78(6):647-55. PubMed ID: 16338280
[TBL] [Abstract][Full Text] [Related]
9. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.
Hynninen VV; Olkkola KT; Neuvonen PJ; Laine K
Eur J Clin Pharmacol; 2009 Jan; 65(1):89-95. PubMed ID: 18777173
[TBL] [Abstract][Full Text] [Related]
10. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.
Geist MJ; Egerer G; Burhenne J; Mikus G
Antimicrob Agents Chemother; 2006 Sep; 50(9):3227-8. PubMed ID: 16940139
[No Abstract] [Full Text] [Related]
11. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Br J Clin Pharmacol; 2007 Jan; 63(1):116-20. PubMed ID: 16822278
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.
Kosuge K; Jun Y; Watanabe H; Kimura M; Nishimoto M; Ishizaki T; Ohashi K
Drug Metab Dispos; 2001 Oct; 29(10):1284-9. PubMed ID: 11560871
[TBL] [Abstract][Full Text] [Related]
14. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.
Niioka T; Uno T; Yasui-Furukori N; Shimizu M; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Oct; 62(10):855-61. PubMed ID: 16915367
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
16. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
17. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
Shi HY; Yan J; Zhu WH; Yang GP; Tan ZR; Wu WH; Zhou G; Chen XP; Ouyang DS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1131-6. PubMed ID: 20669013
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
[TBL] [Abstract][Full Text] [Related]
19. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]